GREGG STONE, Columbia University, New York
New light has been thrown on the use of thienopyridine therapy after percutaneous intervention using drug-eluting stents. Gregg Stone
REFERENCE: American Heart Association Scientific Sessions, Chicago, November 12-15, 2006. Abstract: 2225
JOSEPH MUHLESTEIN, University of Utah , Salt Lake City
Extended follow up of
REFERENCE: American Heart Association Scientific Sessions, Chicago, November 12-15, 2006. Abstract 1948 (C 206) Page: 236, Sunday 12th
OSCAR C MARROQUIN, University of
CHRISTIAN SPAULDING, Cochin Hospital, Paris
REFERENCE: Abstract 1011 to 1016
Tony Gershlick, Leicester University
Drug-eluting stents should not be the favoured option for treating saphenous vein graft lesions according conclusions from a registry analysis presented to the American Heart Association conference by Jeff Trost from Johns Hopkins in Baltimore.
Drug-eluting stents and their additional benefit to low-risk patients were investigated in a cost-effectiveness analysis presented to the Stockholm cardiology meeting by Matthias Pfisterer from Basel. Audio Medica talked with him.